| Q49132332 | "Chemo brain"--is cancer survivorship related to later-life cognition? Findings from the health and retirement study |
| Q38821326 | A Meta-analysis on the neural basis of planning: Activation likelihood estimation of functional brain imaging results in the Tower of London task |
| Q41811696 | A clinically relevant dose of cyclophosphamide chemotherapy impairs memory performance on the delayed spatial alternation task that is sustained over time as mice age. |
| Q47899077 | A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer |
| Q35161191 | A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. |
| Q34083459 | A meta-analysis of cognitive impairment following adult cancer chemotherapy. |
| Q37683581 | A problem-solving task specialized for functional neuroimaging: validation of the Scarborough adaptation of the Tower of London (S-TOL) using near-infrared spectroscopy |
| Q34110937 | A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. |
| Q37743138 | A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy |
| Q38680237 | Acute treatment with doxorubicin affects glutamate neurotransmission in the mouse frontal cortex and hippocampus |
| Q36097701 | Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study |
| Q36528154 | Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage |
| Q30664513 | Alterations in brain structure related to breast cancer and its treatment: chemotherapy and other considerations |
| Q33590378 | Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion |
| Q48419628 | Altered intrinsic brain activity after chemotherapy in patients with gastric cancer: A preliminary study. |
| Q40405501 | Altered neural activation during prepotent response inhibition in breast cancer survivors treated with chemotherapy: an fMRI study |
| Q36287777 | Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors |
| Q34282795 | Altered small-world properties of gray matter networks in breast cancer |
| Q33888300 | Asiatic acid protects against cognitive deficits and reductions in cell proliferation and survival in the rat hippocampus caused by 5-fluorouracil chemotherapy. |
| Q35986398 | Assessing cognitive function in adults during or following chemotherapy: a scoping review |
| Q50532106 | Association of Fatigue Intensification with Cognitive Impairment during Radiation Therapy for Prostate Cancer. |
| Q35744329 | Associations between catecholaminergic, GABAergic, and serotonergic genes and self-reported attentional function in oncology patients and their family caregivers |
| Q38103770 | Autobiographical memory, self, and stress-related psychiatric disorders: which implications in cancer patients? |
| Q39365369 | Brain responses to erotic and other emotional stimuli in breast cancer survivors with and without distress about low sexual desire: a preliminary fMRI study |
| Q48467985 | Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study. |
| Q37211338 | Brain vulnerability to chemotherapy toxicities |
| Q57108220 | Breast cancer treatment and its effects on aging |
| Q47683866 | Cancer Survivorship in Adults |
| Q64095759 | Cancer and cancer survival modulates brain and behavior in a time-of-day-dependent manner in mice |
| Q26853289 | Cancer- and cancer treatment-associated cognitive change: an update on the state of the science |
| Q36299321 | Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. |
| Q36104836 | Changes of Brain Glucose Metabolism in the Pretreatment Patients with Non-Small Cell Lung Cancer: A Retrospective PET/CT Study |
| Q91972438 | Chemobrain as a Product of Growing Success in Chemotherapy - Focus on Glia as both a Victim and a Cure |
| Q27011451 | Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy |
| Q37366039 | Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study |
| Q38904676 | Chemotherapy-Related Neurotoxicity |
| Q37284872 | Chemotherapy-induced amenorrhea: a prospective study of brain activation changes and neurocognitive correlates |
| Q50709662 | Chemotherapy-induced prospective memory impairment in patients with breast cancer. |
| Q37997653 | Chemotherapy-related cognitive dysfunction |
| Q26747612 | Chemotherapy-related cognitive impairment in older patients with cancer |
| Q38088668 | Clearing the air: a review of our current understanding of "chemo fog". |
| Q35164117 | Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults |
| Q42627081 | Cognitive and brain structural changes in a lung cancer population. |
| Q38198215 | Cognitive dysfunction after chemotherapy for breast cancer |
| Q50559589 | Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. |
| Q30572890 | Cognitive function and breast cancer: promise and potential insights from functional brain imaging |
| Q47742422 | Cognitive functioning and emotion processing in breast cancer survivors and controls: An ERP pilot study |
| Q30969661 | Cognitive impairment and associated loss in brain white microstructure in aircrew members exposed to engine oil fumes |
| Q48915541 | Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity |
| Q24594173 | Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors |
| Q42704792 | Decision-making impairments in breast cancer patients treated with tamoxifen |
| Q30830124 | Default mode network as a potential biomarker of chemotherapy-related brain injury |
| Q55267614 | Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. |
| Q48252307 | Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study |
| Q34553351 | Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. |
| Q37694398 | Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment |
| Q37381366 | Dysregulation in myelination mediated by persistent neuroinflammation: possible mechanisms in chemotherapy-related cognitive impairment |
| Q37064264 | Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy |
| Q36473007 | Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study |
| Q36775693 | Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study |
| Q35133442 | Frontal hypometabolism in elderly breast cancer survivors determined by [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET): a pilot study |
| Q30660824 | Functional MRI studies in non-CNS cancers |
| Q48743460 | Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy |
| Q35076356 | Health-related quality of life and cancer clinical trials |
| Q35996167 | Higher cardiorespiratory fitness levels are associated with greater hippocampal volume in breast cancer survivors |
| Q48614501 | Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: a functional MRI study |
| Q47883693 | In vivo neuroimaging and behavioral correlates in a rat model of chemotherapy-induced cognitive dysfunction |
| Q38119468 | Integrating imaging findings in evaluating the post-chemotherapy brain. |
| Q64090826 | Interleukin 1 level, cognitive performance, and severity of depressive symptoms in patients treated with systemic anticancer therapy: a prospective study |
| Q47842217 | International Cognition and Cancer Task Force Recommendations for Neuroimaging Methods in the Study of Cognitive Impairment in Non-CNS Cancer Patients. |
| Q39233062 | Intra-individual variability in women with breast cancer |
| Q43823585 | Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging |
| Q91643978 | Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors |
| Q34395112 | Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. |
| Q50552250 | Metamemory function in chemotherapy-treated patients with breast cancer: an explanation for the dissociation between subjective and objective memory measures? |
| Q59808371 | Mindfulness-based interventions and cognitive function among breast cancer survivors: a systematic review |
| Q36797484 | Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network |
| Q37671653 | Multivariate pattern analysis of FMRI in breast cancer survivors and healthy women |
| Q34661127 | Neurocognitive dimensions of breast cancer and its treatment |
| Q37540122 | Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research |
| Q37292321 | Neuroimaging, cancer, and cognition: state of the knowledge |
| Q55341418 | Neuroimmunology of Behavioral Comorbidities Associated With Cancer and Cancer Treatments. |
| Q34194470 | Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. |
| Q44144688 | Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type |
| Q30596880 | Opening up the window into "chemobrain": a neuroimaging review |
| Q37421024 | Oxidative stress and neurodegenerative disorders |
| Q45111650 | Persistent cognitive changes in breast cancer patients 1 year following completion of chemotherapy |
| Q47966922 | Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats |
| Q37314706 | Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer |
| Q38344507 | Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits. |
| Q35200326 | Potential toxicities of prophylactic cranial irradiation. |
| Q21129407 | Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study |
| Q29395298 | Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: A functional magnetic resonance imaging study |
| Q35617310 | Prefrontal cortex and executive function impairments in primary breast cancer |
| Q38762113 | Prevalence and factors associated with cognitive deficit in women with gynecologic malignancies. |
| Q33854977 | Prevalence, mechanisms, and management of cancer-related cognitive impairment |
| Q50029573 | Quality of Life in Oncology |
| Q39478951 | Quantifying cognitive decrements caused by cranial radiotherapy |
| Q36880990 | Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors |
| Q36450200 | Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls |
| Q40783797 | Relationship between fruit and vegetable intake and interference control in breast cancer survivors |
| Q92244525 | Relationship of Cancer to Brain Aging Markers of Alzheimer's Disease: The Framingham Heart Study |
| Q37982452 | Review of recent studies on interventions for cognitive deficits in patients with cancer |
| Q45343540 | Selective impairment of attention networks in breast cancer patients receiving chemotherapy treatment |
| Q89111014 | Self-reported chemotherapy-related cognitive impairment compared with cognitive complaints following menopause |
| Q37725264 | Subtle hippocampal deformities in breast cancer survivors with reduced episodic memory and self-reported cognitive concerns |
| Q88575267 | Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment |
| Q34562855 | Systemic chemotherapy decreases brain glucose metabolism |
| Q49283402 | The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study |
| Q47202351 | The usefulness of sLORETA in evaluating the effect of high-dose ARA-C on brain connectivity in patients with acute myeloid leukemia: an exploratory study |
| Q45958149 | Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. |
| Q55162138 | Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors. |
| Q48162355 | Verbal memory in breast cancer patients treated with chemotherapy with doxorubicin and cyclophosphamide |
| Q41663182 | Very Late Treatment-Related Alterations in Brain Function of Breast Cancer Survivors |
| Q48054964 | Visuospatial planning in unmedicated major depressive disorder and bipolar disorder: distinct and common neural correlates |
| Q95482348 | [In Process Citation] |
| Q84061088 | [Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. The radiation-oncological view] |